Technical Analysis for ITCI - Intra-Cellular Therapies Inc.

Grade Last Price % Change Price Change
grade F 12.55 -0.48% -0.06
ITCI closed down 0.48 percent on Friday, January 18, 2019, on 1.33 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ITCI trend table...

Date Alert Name Type % Chg
Jan 18 Hammer Candlestick Bullish 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 17 Weak + Overbought Other -0.48%
Jan 17 Wide Bands Range Expansion -0.48%
Jan 17 Overbought Stochastic Strength -0.48%
Jan 16 Weak + Overbought Other -4.05%
Jan 16 Wide Bands Range Expansion -4.05%

Older signals for ITCI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
Is ITCI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 25.82
52 Week Low 10.21
Average Volume 413,626
200-Day Moving Average 18.6962
50-Day Moving Average 14.0654
20-Day Moving Average 12.0285
10-Day Moving Average 12.902
Average True Range 0.8299
ADX 23.32
+DI 18.2296
-DI 25.9256
Chandelier Exit (Long, 3 ATRs ) 11.1003
Chandelier Exit (Short, 3 ATRs ) 12.6997
Upper Bollinger Band 13.9327
Lower Bollinger Band 10.1243
Percent B (%b) 0.64
BandWidth 31.661471
MACD Line -0.233
MACD Signal Line -0.4584
MACD Histogram 0.2255
Fundamentals Value
Market Cap 544.97 Million
Num Shares 43.4 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -5.32
Price-to-Sales 2144.19
Price-to-Book 1.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.29
Resistance 3 (R3) 13.26 12.99 13.16
Resistance 2 (R2) 12.99 12.80 13.00 13.12
Resistance 1 (R1) 12.77 12.69 12.64 12.80 13.08
Pivot Point 12.50 12.50 12.43 12.51 12.50
Support 1 (S1) 12.28 12.31 12.15 12.31 12.02
Support 2 (S2) 12.01 12.20 12.02 11.98
Support 3 (S3) 11.79 12.01 11.94
Support 4 (S4) 11.82